- Home
- FNLC vs DMAC Comparison
FNLC vs DMAC Comparison
Compare FNLC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- DMAC
- Stock Information
- Founded
- FNLC 1864
- DMAC 2000
- Country
- FNLC United States
- DMAC United States
- Employees
- FNLC N/A
- DMAC N/A
- Industry
- FNLC Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- DMAC Health Care
- Exchange
- FNLC Nasdaq
- DMAC Nasdaq
- Market Cap
- FNLC 295.4M
- DMAC 274.1M
- IPO Year
- FNLC 1999
- DMAC N/A
- Fundamental
- Price
- FNLC $26.77
- DMAC $4.82
- Analyst Decision
- FNLC
- DMAC Strong Buy
- Analyst Count
- FNLC 0
- DMAC 3
- Target Price
- FNLC N/A
- DMAC $7.00
- AVG Volume (30 Days)
- FNLC 17.6K
- DMAC 118.6K
- Earning Date
- FNLC 01-22-2025
- DMAC 11-13-2024
- Dividend Yield
- FNLC 5.20%
- DMAC N/A
- EPS Growth
- FNLC N/A
- DMAC N/A
- EPS
- FNLC 2.38
- DMAC N/A
- Revenue
- FNLC $78,192,000.00
- DMAC N/A
- Revenue This Year
- FNLC N/A
- DMAC N/A
- Revenue Next Year
- FNLC N/A
- DMAC N/A
- P/E Ratio
- FNLC $11.64
- DMAC N/A
- Revenue Growth
- FNLC N/A
- DMAC N/A
- 52 Week Low
- FNLC $21.77
- DMAC $2.14
- 52 Week High
- FNLC $31.05
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- FNLC 31.37
- DMAC 47.28
- Support Level
- FNLC $26.12
- DMAC $5.05
- Resistance Level
- FNLC $28.16
- DMAC $5.74
- Average True Range (ATR)
- FNLC 0.65
- DMAC 0.37
- MACD
- FNLC -0.35
- DMAC -0.08
- Stochastic Oscillator
- FNLC 0.00
- DMAC 28.10
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.